ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

On-and-off fasting helps fight obesity, study finds

Can Pomegranates Slow Aging?

Calorie restriction promotes longevity through effects on mitochondrial network

Discover Why Ashwagandha Can Be Used for Stress and Anxiety

How Can You Benefit From Vitamin B12?

A spoonful of oil: Fats and oils help to unlock full nutritional benefits of veggies, study suggests

Lower magnesium levels linked with increased mortality risk during up to 40 years of follow-up

Higher resveratrol dose linked to lower glucose levels in type 2 diabetics

What Is Bitter Orange?

Drug can dramatically reduce weight of people with obesity

 
Print Page
Email Article

Abstract: Oral Triptans (Serotonin 5-HT1B/1D Agonists) in Acute Migraine Treatment: A Meta-Analysis of 53 Trials

  [ 22 votes ]   [ Discuss This Article ]
By Michel D. Ferrari , Krista I. Roon, Richard B. Lipton, Peter J. Goadsby • www.ProHealth.com • November 21, 2001




Department of Neurology, Leiden University Medical Centre, 2300 RC Leiden, Albinusdreef 2, 2333 ZA Leiden, Netherlands (M D Ferrari MD, K I Roon MD); Departments of Neurology, Epidemiology and Social Medicine, Albert Einstein College of Medicine and the Montefiore Headache Unit, New York, and Innovative Medical Research Inc, Stamford, CT, USA (R B Lipton MD); Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK (P J Goadsby MD).

Correspondence to: Dr. Michel D. Ferrari (e-mail:M.D.Ferrari@LUMC.NL)

Background: The triptans, selective serotonin 5-HT1B/1D agonists, are very effective acute migraine drugs with a well-developed scientific rationale. Seven different triptans will soon be clinically available, making evidence-based selection guidelines necessary. Triptan trials have similar designs, facilitating meta-analysis; this will provide a foundation for using triptans in clinical practice.

Method: We asked pharmaceutical companies and the principal investigators of company-independent trials for raw patient data of all double-blind, randomized, controlled, clinical trials of oral triptans in migraine. We calculated summary estimates across studies for important efficacy and tolerability parameters, and separately summarized direct comparator trials.

Results: 53 clinical trials (12 unpublished) involving 24 089 patients, met the criteria for inclusion. Mean results for 100 mg sumatriptan were 59% (95% CI 57-60) for 2 h headache response (improvement from moderate or severe to mild or no pain); 29% (27-30) for 2 h pain free (improvement to no pain); 20% (18-21) for sustained pain free (pain free by 2 h and no headache recurrence or use of rescue medication 2-24 h post dose); and 67% (63-70) for consistency (response in at least two of three treated attacks); placebo-subtracted proportions for patients with at least one adverse event (AE) were 13% (8-18), for at least one central nervous system AE 6% (3-9), and for at least one chest AE 1·9% (1·0-2·7).

Compared with these data, 10 mg rizatriptan showed better efficacy and consistency, and similar tolerability; 80 mg eletriptan showed better efficacy, similar consistency, but lower tolerability; 12·5 mg almotriptan showed similar efficacy at 2 h but better other results; 2·5 mg naratriptan 20 mg eletriptan showed lower efficacy and (the first two) better tolerability; and 2·5 mg and 5 mg zolmitriptan, 40 mg eletriptan, and 5 mg rizatriptan showed very similar results. The results of the 22 trials that directly compared triptans show the same overall pattern. We received no data on frovatriptan, but publicly available data suggest lower efficacy.

Interpretation: At marketed doses, all oral triptans were effective and well tolerated. 10 mg rizatriptan, 80 mg eletriptan, and 12·5 mg almotriptan provide the highest likelihood of consistent success.

Source: The Lancet 2001; 358: 1668-75




Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Ultra ATP+, Double Strength FibroSleep™


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Strengthen Cell Function with Energy-Boosting Niagen Strengthen Cell Function with Energy-Boosting Niagen
When a Good Night's Sleep Is Just a Daydream... When a Good Night's Sleep Is Just a Daydream...
Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage The Cellular Enzyme That Promotes Longevity And Reduces Fat Storage
SAD? Coping with Seasonal Affective Disorder SAD? Coping with Seasonal Affective Disorder

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map